British Journal of Anaesthesia, 2002, Vol. 89, No. 6 846-848
© 2002 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Plasma lidocaine concentrations following insertion of 2% lidocaine gel into the uterine cavity after uterine balloon thermal ablation
1 Department of Anaesthesia, North Devon District Hospital, Barnstaple EX31 4JB, UK. 2 Department of Anaesthesia and Intensive Care and 3 Department of Obstetrics and Gynaecology, Torbay Hospital, Torquay TQ2 7AA, UK. 4 Pharmacy Department, Derriford Hospital, Plymouth PL6 8DH, UK guy.rousseau@virgin.net
Background. Uterine balloon thermal ablation is used to treat menorrhagia. We thought that intrauterine application of 2% lidocaine gel could reduce postoperative pain after this procedure. Before using this technique we wished to establish how much lidocaine is absorbed systemically from the uterine cavity after thermal ablation.
Methods. Ten ASA III patients (age 3850 yr) underwent uterine balloon thermal ablation under general anaesthesia. They each had 11 ml of 2% lidocaine gel (InstillagelTM) inserted into the uterine cavity at the end of the procedure. Blood samples were taken at 5, 15, 30 and 60 min after insertion and lidocaine concentrations were measured using high-performance liquid chromatography.
Results. Mean (range) plasma lidocaine concentrations at 5, 15, 30 and 60 min were 40.3 (0221.9), 66.3 (0271.9), 64.9 (0208) and 75 (0212) ng ml1, respectively.
Conclusion. There was minimal systemic absorption of lidocaine from the uterus following uterine balloon thermal ablation. Measured concentrations were well below the toxic plasma concentration for lidocaine (810 µg ml1).
Br J Anaesth 2002; 89: 8468